FBIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FBIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Fortress Biotech's quarterly common stock increased from Mar. 2024 ($0.02 Mil) to Jun. 2024 ($0.02 Mil) and increased from Jun. 2024 ($0.02 Mil) to Sep. 2024 ($0.03 Mil).
Fortress Biotech's annual common stock declined from Dec. 2021 ($0.10 Mil) to Dec. 2022 ($0.01 Mil) but then increased from Dec. 2022 ($0.01 Mil) to Dec. 2023 ($0.02 Mil).
The historical data trend for Fortress Biotech's Common Stock can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fortress Biotech Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Common Stock | Get a 7-Day Free Trial | 0.57 | 0.10 | 0.10 | 0.01 | 0.02 |
Fortress Biotech Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Common Stock | Get a 7-Day Free Trial | 0.01 | 0.02 | 0.02 | 0.02 | 0.03 |
Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.
The par value of common stocks is meaningless. It is usually set at an absurdly low number.
Rosenwald Lindsay A Md | director, 10 percent owner, officer: PRESIDENT, CEO & CHAIRMAN | 375 PARK AVE, NEW YORK NY 10152 |
Dov Klein | director | C/O FORTRESS BIOTECH, INC., 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019 |
Lucy Lu | director | THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137 |
David Jin | officer: Chief Financial Officer | C/O AVENUE THERAPEUTICS, INC., 1140 AVENUE OF THE AMERICAS, FLOOR 9, NEW YORK NY 10036 |
Robyn Hunter | officer: Chief Financial Officer | 95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453 |
Eric K Rowinsky | director | IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014 |
Malcolm Hoenlein | director | 750 LEXINGTON AVENUE, NEW YORK NY 10022 |
Jimmie Harvey | director | 3741 EAST FAIRWAY DRIVE, BIRMINGHAM AL 35213 |
J Jay Lobell | director | 365 W END AVE, APARTMENT 10A, NEW YORK NY 10024 |
Michael S Weiss | director, 10 percent owner, officer: EXECUTIVE VICE CHAIRMAN | 750 LEXINGTON AVE, NEW YORK NY 10022 |
Kevin Lorenz | director | C/O NUVEEN, 333 W. WACKER DR., CHICAGO IL 60606 |
George Avgerinos | officer: SVP, Biologics Operations | C/O CORONADO BIOSCIENCES, INC., 24 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803 |
Kevin Horgan | other: Former Chief Medical Officer | C/O SOLIGENIX, INC., 29 EMMONS DRIVE, STE. C-10, PRINCETON NJ 08540 |
David Jonathan Barrett | director | ONE PENN PLAZA, SUITE 2514, NEW YORK NY 10119 |
Harlan F Weisman | director | C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803 |
From GuruFocus
By GuruFocus Research • 02-07-2024
By Marketwired • 10-16-2023
By GlobeNewswire • 11-09-2023
By GuruFocus Research • 02-07-2024
By PRNewswire • 12-06-2023
By GuruFocus Research • 02-07-2024
By GuruFocus News • 11-14-2024
By GuruFocus Research • 02-07-2024
By GuruFocus News • 10-25-2024
By PRNewswire • 12-04-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.